What question did this study set out to answer?

This study aims to evaluate the plasma ATN biomarkers in distinguishing Alzheimer's disease stages in a Latin American cohort.

February 16, 2026Alzheimer s Research & TherapyOpen Access

Plasma ATN biomarkers across the alzheimer’s disease continuum in a Chilean community- and clinic-based cohort

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the plasma ATN biomarkers in distinguishing Alzheimer's disease stages in a Latin American cohort.
Examined plasma biomarkers including Aβ42/Aβ40, p-tau217, and NfL in 318 older adults.
Used ANCOVA for group differences and linear regression for associations with cognitive performance.
Implemented machine-learning models with cross-validation to classify diagnostic categories.
Progressive decline in Aβ42/Aβ40 ratio and increase in p-tau217 across clinical stages observed.
Inversely associated levels of p-tau217 and NfL with cognitive and functional performance.
p-tau217 accurately distinguished Alzheimer's dementia from cognitively unimpaired individuals (AUC = 0.88).

Authors

POPaulina OrellanaAdolfo Ibáñez University FHFernando HenríquezPontificia Universidad Católica de Chile FCFelipe Cabral-MirandaUniversidade Federal do Rio de Janeiro

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Analysis reveals plasma biomarkers improve differentiation of Alzheimer’s disease stages in older adults, suggesting clinical relevance for cognitive performance.

Cite This Study

Orellana et al. (2026) studied this question.

synapsesocial.com/papers/69926a620d0ce0adc9976aa0 https://doi.org/10.1186/s13195-026-01974-0

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals plasma biomarkers improve differentiation of Alzheimer’s disease stages in older adults, suggesting clinical relevance for cognitive performance.

Plasma ATN biomarkers across the alzheimer’s disease continuum in a Chilean community- and clinic-based cohort

Key Points

Discussion

Implication

Cite This Study

Plasma ATN biomarkers across the alzheimer’s disease continuum in a Chilean community- and clinic-based cohort

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider